{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T23:24:17Z","timestamp":1649201057833},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T00:00:00Z","timestamp":1458604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00120-015-0021-1","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T08:55:47Z","timestamp":1458636947000},"page":"627-631","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kardiovaskul\u00e4re Risiken der Androgendeprivationstherapie beim Prostatakarzinom"],"prefix":"10.1007","volume":"55","author":[{"given":"K.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,22]]},"reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00432-006-0134-4","volume":"132","author":"M Mason","year":"2006","unstructured":"Mason M (2006) What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care. J Cancer Res Clin Oncol 132:27\u201335","journal-title":"J Cancer Res Clin Oncol"},{"key":"21_CR2","unstructured":"AWMF\/DKG\/DeutscheKrebshilfe (2914) Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms"},{"key":"21_CR3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","volume":"132","author":"J Seidenfeld","year":"2000","unstructured":"Seidenfeld J, Samson DJ, Hasselblad V et al (2000) Single-therapy androgen suppression in men with advanced prostate cancer. A systematic review and meta-analysis. Ann Intern Med 132:566\u2013577","journal-title":"Ann Intern Med"},{"key":"21_CR4","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase\u00a0III study in patients with prostate cancer. Br J Urol Int 102:1531\u20131538","journal-title":"Br J Urol Int"},{"key":"21_CR5","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","volume":"25","author":"AV D\u2019Amico","year":"2007","unstructured":"D\u2019Amico AV, Denham JW, Crook J et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420\u20132425","journal-title":"J Clin Oncol"},{"key":"21_CR6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493\u20131500","journal-title":"Cancer"},{"key":"21_CR7","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448\u20134456","journal-title":"J Clin Oncol"},{"key":"21_CR8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102:39\u201346","journal-title":"J Natl Cancer Inst"},{"key":"21_CR9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","volume":"65","author":"CG Jespersen","year":"2014","unstructured":"Jespersen CG, Norgaard M, Androgen-Borre M (2014) deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 65:704\u2013709","journal-title":"Eur Urol"},{"key":"21_CR10","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","volume":"9","author":"J Zhao","year":"2014","unstructured":"Zhao J, Zhu S, Sun L et al (2014) Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PloS One 9:e107516","journal-title":"PloS One"},{"key":"21_CR11","doi-asserted-by":"crossref","first-page":"529468","DOI":"10.1155\/2014\/529468","volume":"2014","author":"G Huang","year":"2014","unstructured":"Huang G, Yeung CY, Lee KK et al (2014) Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. J Oncol 2014:529468","journal-title":"J Oncol"},{"issue":"9","key":"21_CR12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00345-014-1439-6","volume":"33","author":"A Carneiro","year":"2014","unstructured":"Carneiro A, Sasse AD, Wagner AA et al (2014) Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol 33(9):1281\u20131289","journal-title":"World J Urol"},{"key":"21_CR13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565\u2013573","journal-title":"Eur Urol"},{"key":"21_CR14","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FB et al (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 306:2359\u20132366","journal-title":"JAMA"},{"key":"21_CR15","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2011.04.067","volume":"82","author":"PL Nguyen","year":"2012","unstructured":"Nguyen PL, Chen M-H, Beckman JA et al (2012) Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 82:1411\u20131416","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"21_CR16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","volume":"116","author":"DR Ziehr","year":"2014","unstructured":"Ziehr DR, Chen MH, Zhang D et al (2014) Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. Br J Urol Int 116(3):358\u2013365","journal-title":"Br J Urol Int"},{"key":"21_CR17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D\u2019Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516\u20131524","journal-title":"J Natl Cancer Inst"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","volume":"302","author":"A Nanda","year":"2009","unstructured":"Nanda A, Chen MH, Braccioforte MH, Moran BJ, D\u2019Amico AV (2009) Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302:866\u2013873","journal-title":"JAMA"},{"key":"21_CR19","unstructured":"Robert Koch-Institut (Hrsg) (2014) Gesundheitliche Lage der M\u00e4nner in Deutschland. Berlin"},{"key":"21_CR20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamainternmed.2014.3028","volume":"174","author":"GL Lu-Yao","year":"2014","unstructured":"Lu-Yao GL, Albertsen PC, Moore DF et al (2014) Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. Jama Intern Med 174:1460\u20131467","journal-title":"Jama Intern Med"},{"key":"21_CR21","unstructured":"Mottet N, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. http:\/\/www.uroweb.org\/gls\/pdf\/09 Prostate Cancer_LRLV2.pdf. Zugegriffen: 21.03.2015"},{"key":"21_CR22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3322\/caac.20061","volume":"60","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P et al (2010) Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 60:194\u2013201","journal-title":"CA Cancer J Clin"},{"key":"21_CR23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","volume":"54","author":"JA Efstathiou","year":"2008","unstructured":"Efstathiou JA, Bae K, Shipley WU et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92\u201302. Eur Urol 54:816\u2013824","journal-title":"Eur Urol"},{"key":"21_CR24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI63108","volume":"123","author":"AH Lichtman","year":"2013","unstructured":"Lichtman AH, Binder CJ, Tsimikas S, Witztum JL (2013) Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest 123:27\u201336","journal-title":"J Clin Invest"},{"key":"21_CR25","first-page":"743","volume":"84","author":"HF Chen","year":"1999","unstructured":"Chen HF, Jeung EB, Stephenson M, Leung PC (1999) Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 84:743\u2013750","journal-title":"J Clin Endocrinol Metab"},{"key":"21_CR26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.eururo.2013.11.016","volume":"65","author":"DJ Rosario","year":"2014","unstructured":"Rosario DJ, Bourke L, Keating NL (2014) Androgen deprivation therapy and cardiovascular harm: are all men created equal. Eur Urol 65:574\u2013576","journal-title":"Eur Urol"},{"key":"21_CR27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eururo.2013.09.040","volume":"65","author":"L Bourke","year":"2014","unstructured":"Bourke L, Gilbert S, Hooper R et al (2014) Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 65:865\u2013872","journal-title":"Eur Urol"},{"issue":"5","key":"21_CR28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2014","unstructured":"Nguyen PL, Alibhai SM, Basaria S et al (2014) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825\u2013836","journal-title":"Eur Urol"},{"key":"21_CR29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2013.49.5523","volume":"32","author":"JR Gardner","year":"2014","unstructured":"Gardner JR, Livingston PM, Fraser SF (2014) Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32:335\u2013346","journal-title":"J Clin Oncol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-0021-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-015-0021-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-0021-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T07:04:34Z","timestamp":1558595074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-015-0021-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,22]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s00120-015-0021-1","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,22]]}}}